-
Chardan Reiterates Sell On Esperion, Cites 'Lack Of Visibility' And 'Possibility Of Declining Efficacy'
Tuesday, July 28, 2015 - 11:52am | 319Read More...In a report published Tuesday, Chardan Capital Markets analyst Gbola Amusa reiterated a Sell rating on shares of Esperion Therapeutics Inc (NASDAQ: ESPR) with a $40 price target following the release of a phase II results from Study 014 which tested ETC-1002 over six weeks in patients with...
